

## Vermont Vaccine Purchasing Program Assessment Calculation Worksheet

Column →	A	B	C	D	E	F	G
	CHILDREN			ADULTS			
Line ↓	Prior	2018		Prior	2018		Comments
<b>A. Preliminary Vaccine Cost Estimates</b>							
01.	14,966,755	13,772,656		1,934,562	3,233,711		Estimated costs of vaccines (sheets e & f)
02.	1,497	1,377	0.01%	29,018	16,169	0.50%	Provision for vaccine utilization increase
03.	359,238	361,568	3.50%	17,918	56,873	3.50%	<sup>1</sup> Provision for vaccine cost increase (% is annual)
04.	15,327,490	14,135,601		1,981,498	3,306,753		Est. vaccines costs( w/ utilization & price adjustments.)
05.	-8,477,222	-7,998,850		-338,378	-380,110		Estimated VFC Award & 317 federal grant
06.	0	0		0	0		Other
07.	6,850,268	6,136,751		1,643,120	2,926,643		Estimated VVPP vaccine costs
08.	171,257	227,060	3.70%	41,078	108,286	3.70%	VDH administrative fee
09.	793,475	0		263,085	0		CDC Advance Funding Amortization (ended in 2017 )
10.	<b>7,815,000</b>	<b>6,363,811</b>		<b>1,947,283</b>	<b>3,034,929</b>		Total vaccine and VDH administrative costs
<b>B. Assessable Covered Lives Estimates</b>							
11.	57,990	60,130		360,433	350,832		Assessable covered lives (sheet c)
12.	870	0	0.00%	5,406	1,737	0.50%	Leakage (unknown insurer, out of reach entity, etc.)
13.	<b>57,120</b>	<b>60,130</b>		<b>355,027</b>	<b>349,095</b>		Assessable lives actually paying
<b>C. Financial Carry Forwards</b>							
14.	674,169	604,594		113,293	78,160		Vaccine fund carryforward (sheet d.)
15.	0	0	0.0	0	0	0.0	Amt. retained for liquidity reserve /reserve months
16.	<b>674,169</b>	<b>604,594</b>		<b>113,293</b>	<b>78,160</b>		Carryforward used to reduce current assessment
<b>D. Operational and Other Fixed Costs</b>							
17.	137,231	117,851		35,246	60,505		Total administrative budget (from sheet b.)
18.	17,852	636	0.01%	4,585	303	0.01%	Bad debt allowance
19.	155,083	118,487		39,831	60,808		Sub-total anticipated operating costs
20.	892,604	0	0.00%	229,249	0	0.00%	Working capital reserve build-up
21.	0	0	0.00%	0	0	0.00%	Risk reserves
22.	<b>\$ 1,047,687</b>	<b>\$ 118,487</b>		<b>\$ 269,080</b>	<b>\$ 60,808</b>		Total fixed costs
<b>E. Assessment Calculation</b>							
23.	\$ 8,862,687	\$6,482,298		\$ 2,216,363	\$3,095,737		Total assessment funds needed (Row 10+ Row 22)
24.	\$ (674,169)	-\$604,594		\$ (113,293)	-\$78,160		Plus carry forward credit
25.	<b>\$ 8,188,518</b>	<b>\$5,877,704</b>		<b>\$ 2,103,070</b>	<b>\$3,017,576</b>		Net assessment funds needed
<b>F. Per Assessable Covered Life Assessment</b>							
26.	\$143.36	\$97.80		\$5.92	\$8.64		Annual assessment per covered life
27.	\$11.95	<b>\$8.15</b>		\$0.50	<b>\$0.72</b>		<b>Monthly assessment per covered life calculated</b>
28.	\$11.95	<b>\$8.15</b>		\$0.50	<b>\$0.72</b>		<b>Monthly assessment per covered life recommended</b>
<b>G. Unexpended Assessments</b>							
29.	910,456	636		233,834	303		<sup>2</sup> Unexpended assessments
<b>H. Various Performance Metrics</b>							
30.	2.00%	1.92%		2.15%	2.07%		VVPP operational costs as % of vaccine costs
31.	4.76%	5.63%		4.92%	5.78%		Lines 8 + 19 as % of vaccines
32.	11.37%	-31.80%		-13.79%	44.00%		% year to year change in assessment rate
33.	\$ 10.47	\$8.98		\$0.40	\$0.74		<sup>3</sup> "Normalized" assessment rate (w/o lines 9, 14, & 20)
<b>I. Vaccine Cost per Covered Life determination</b>							
34.	\$ 9.84	<b>\$ 8.50</b>		\$ 0.38	<b>\$ 0.70</b>		Vaccine cost calculated
35.	\$ 9.84	<b>\$ 8.50</b>		\$ 0.38	<b>\$ 0.70</b>		Vaccine cost recommended

**Notes:**

<sup>1</sup> The provision for cost increases is applied for 9 months for childhood vaccines and 6 months for adult vaccines in developing the line 01. cost estimates. (This is due to the respective contract change dates, i.e. 4/1 for childhood vaccines and 7/1 for adult vaccines.)

<sup>2</sup> Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.

<sup>3</sup> This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.

**VT DOH Pediatric Vaccine Purchase Estimates  
Federal Fiscal Year 18**

Column →  
Line ↓

	A	B	C	D	E	F	G	H	I
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP Cost Per Dose <sup>1</sup>	Total Estimated Doses	Total Estimated Cost
01.	DTaP	Daptacel	49281-0286-10	\$16.73	450	\$7,572	\$17.16	960	\$16,474
02.		Infanrix	58160-0810-11	\$16.85	6,150	\$106,268	\$17.73	6,550	\$116,132
03.	DTaP-HepB-IPV	Pediarix	58160-0811-52	\$54.90	12,840	\$714,708	\$56.43	13,340	\$752,776
04.	DTaP-IPV/Hib	Pentacel	49281-0510-05	\$56.91	4,475	\$254,284	\$56.738	6,520	\$369,932
05.	DTaP-IPV	Kinrix	58160-0812-11	\$39.57	6,430	\$254,435	\$39.57	5,310	\$210,117
06.		Quadracel	49281-0562-10	N/A	0	\$0	\$39.57	1,640	\$64,895
07.		ActiHIB	49281-0545-05	\$9.55	18,525	\$176,914	\$9.55	19,375	\$185,031
08.	Hib	PedvaxHIB	00006-4897-00	\$12.48	0	\$0	\$12.79	0	\$0
09.		Hiberix	58160-0818-11	\$9.46	\$0	\$0	\$9.46	0	\$0
10.	HepA	Vaqta	00006-4831-41	\$18.23	0	\$0	\$18.75	0	\$0
11.		Havrix	58160-0825-11	\$17.83	20,890	\$381,810	\$18.68	21,000	\$392,280
12.	HepB	Recombivax	00006-4981-00	\$12.30	0	\$0	\$12.30	0	\$0
13.		Engerix B	58160-0820-52	\$11.60	7,230	\$85,114	\$12.30	9,140	\$112,422
14.	HepA-HepB	Twinrix	58160-0815-52	\$56.97	10	\$570	\$56.97	0	\$0
15.	HPV	(HPV9) Gardasil	00006-4119-03	\$141.60	19,480	\$2,837,551	\$154.28	18,850	\$2,908,178
16.	IPV	IPOL	49281-0860-10	\$12.72	2,640	\$34,022	\$13.04	2,000	\$26,080
17.			49281-0625-15	\$13.77	25,350	\$349,070	N/A	N/A	N/A
18.		Fluzone - Quad	49281-0516-25	\$19.143	16,000	\$306,288	N/A	N/A	N/A
19.	Influenza		49281-0416-50	\$14.925	17,900	\$267,158	N/A	N/A	N/A
20.			49281-0416-10	\$15.818	4,550	\$71,972	N/A	N/A	N/A
21.		Fluarix - Quad	58160-0905-52	\$14.430	1,200	\$17,316	N/A	N/A	N/A
22.		Fluzone - Quad	49281-0417-50	N/A	0	\$0	\$15.675	37,250	\$583,894
23.	Influenza		49281-0517-25	N/A	0	\$0	\$15.675	14,450	\$226,504
24.		FluLaval	19515-0912-52	N/A	0	\$0	\$14.430	12,800	\$184,704
25.	MMR	MMR II	00006-4681-00	\$20.11	6,800	\$138,615	\$20.59	8,300	\$170,897
26.	MMRV	ProQuad	00006-4171-00	\$114.25	6,760	\$788,288	\$118.72	7,400	\$878,528
27.	MCV4	Menactra	49281-0589-05	\$89.16	12,430	\$1,108,259	\$89.16	11,390	\$1,015,532
28.		Menveo	58160-0955-09	\$68.32	275	\$20,022	\$71.70	240	\$17,208
29.	MENB	Trumenba	00005-0100-10	\$95.75	0	\$0	\$100.98	0	\$0
30.		Bexsero	58160-0976-06	\$98.51	1,362	\$141,014	\$98.51	2,125	\$209,334
31.	PCV13	Prenvar 13	00005-1971-02	\$120.39	23,150	\$2,862,304	\$126.97	25,000	\$3,174,250
32.	PPSV23	Pneumovax 23	00006-4943-00	\$46.40	130	\$6,146	\$48.72	230	\$11,206
33.		(RV5) RotaTeq	00006-4047-41	\$66.49	230	\$15,556	\$69.12	230	\$15,898
34.	RV	(RV1) Rotarix	58160-0854-52	\$86.75	10,430	\$927,894	\$91.05	12,000	\$1,092,600
35.	Td	Tenivac	49281-0215-10	\$19.69	134	\$2,638	\$19.69	0	\$0
36.		Td Vaccine	13533-0131-01	\$13.20	476	\$6,039	\$12.513	745	\$9,322
37.	Tdap	Boostrix	58160-0842-11	\$31.37	8,120	\$255,038	\$31.37	4,200	\$131,754
38.		Adacel	49281-0400-10	\$31.37	1,170	\$36,509	\$30.99	5,000	\$154,950
39.	VAR	Varivax	00006-4827-00	\$88.34	7,290	\$660,555	\$92.72	8,000	\$741,760
40.		<b>Totals:</b>			<b>242,877</b>	<b>\$12,833,924</b>		<b>254,045</b>	<b>\$13,772,656</b>
41.									<b>Adjusted for utilization Increase</b>
42.									<b>\$13,774,033</b>
43.									<b>Further adjusted for price increase</b>
44.									<b>\$14,135,601</b>
43.				<u>Dollars</u>	<u>%</u>				
44.		VFC award		<b>\$7,998,850</b>	<b>56.59%</b>				<b>-\$7,998,850</b>

Notes:

<sup>1</sup> CDC pediatric vaccine contract purchase prices as of 9/1/17

**VT DOH Adult Vaccine Purchase Estimates  
Federal Fiscal Year 18**

Column →  
Line ↓

	A	B	C	D	E	F	G	H	I
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP cost per dose <sup>1</sup>	Total Estimated Doses	Total Estimated Cost
01.	HepA	Vaqta	00006-4096-02	\$27.68	0	\$0	\$31.18	0	\$0
02.		Havrix	58160-0826-11	\$25.73	3,230	\$83,108	\$25.73	4,700	\$120,931
03.	HepB	Engerix B	58160-0821-52	\$25.33	3,970	\$104,114	\$29.38	4,810	\$141,318
04.	HepA-HepB	Twinrix	58160-0815-52	\$54.66	1,290	\$70,983	\$55.90	1,600	\$89,440
05.	HPV	(HPV9) Gardasil	00006-4119-03	\$119.04	1,400	\$163,328	\$116.22	2,520	\$292,874
06.	Influenza	Fluarix	58160-0907-52	\$12.72	400	\$5,088	\$12.72	400	\$5,088
07.	MMR	MMR II	00006-4681-00	\$40.00	110	\$4,527	\$42.12	505	\$21,271
08.	MCV4	Menactra	49281-0589-05	\$74.334	305	\$22,872	\$76.152	600	\$45,691
09.		Menveo	58160-0955-09	\$72.45	0	\$0	\$69.74	35	\$2,441
10.	MENB	Trumenba	00005-0100-10	\$85.54	0	\$0	\$82.22	0	\$0
11.		Bexsero	58160-0976-06	\$117.49	139	\$14,876	\$106.28	250	\$26,570
12.	PCV13	Prevnar 13	00005-1971-02	\$96.56	530	\$54,089	\$112.74	890	\$100,336
13.	PPSV23	Pneumovax 23	00006-4943-00	\$26.15	5,190	\$158,213	\$47.80	5,775	\$276,045
14.	Td	Tenivac	49281-0215-10	\$12.271	701	\$8,735	\$13.575	0	\$0
15.		Td Vaccine	13533-0131-01	\$13.20	3,698	\$47,951	\$13.575	6,620	\$89,867
16.	Tdap	Boostrix	58160-0842-11	\$24.39	13,940	\$339,669	\$24.36	14,000	\$341,040
17.		Adacel	49281-0400-10	\$23.724	2,940	\$70,532	\$24.769	3,000	\$74,307
18.	VAR	Varivax	00006-4827-00	\$66.36	40	\$2,690	\$69.94	50	\$3,497
19.	Zoster	Shingrix (HZ/su)*	58160-0823-11	N/A	0	\$0	\$105.00	14,500	\$1,522,500
20.		Zostavax (ZVL)	00006-4963-41	\$117.12	5,310	\$643,207	\$134.16	600	\$80,496
21.	Weighted Average						\$53.14		
22.	Totals:				43,193	\$1,793,982		60,855	\$3,233,711
23.					Adjusted for utilization increase				\$3,249,880
24.					Further adjusted for price increase				\$3,306,753
25.					Dollars	%			
	Estimated 317 Funding				\$380,110	11.49%			-\$380,110

<sup>1</sup> CDC adult vaccine contract purchase prices as of 9/1/17

\*Shingrix cost unavailable, estimated at 75% of private cost

## Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
Revenues			
01.	Carryforward from prior year	\$0.00	
02.	VVPP assessment collections over federal fiscal year	\$10,194,574.84	
03.	317 grant funds received	\$330,766.12	
04.	VFC (including VFC flu)	\$7,565,216.33	
05.	TRICARE settlement <sup>1</sup>	\$785,867.00	
06.	Payment made during the period but due from	\$77,216.09	
07.	prior period)		
08.			
09.			\$18,953,640.38
Expenditures / Allowances			
10.	State bulk purchase	\$7,319,193.30	
11.	State Flu	\$431,547.60	
12.	State direct ship	\$1,187,290.60	
13.	VFC (including VFC flu) vaccine purchases	\$7,565,216.33	
14.	KidsVax <sup>2</sup>	\$167,977.00	
15.	VDH administration fee	\$212,335.00	
16.	Year 3 of 3 of initial cash amortization	\$1,056,559.94	
17.	317 program vaccine purchases	\$330,766.12	
18.			<u>-\$18,270,885.89</u>
19.	Vaccine Fund Carryforward <sup>3</sup> (applied to reduce this year's assessment)		<u>\$682,754.49</u>
		<u>Child</u>	<u>Adult</u>
20.	No cash amortization <sup>4</sup>	\$0.00	\$0.00

**Notes:**

<sup>1</sup> Initial settlement amount offered by Tricare, final settlement may be higher.

<sup>2</sup> Full amount of KidsVax contract through 12/31/2017.

<sup>3</sup> Excess of revenues (including prior carryforward) over expenditures.

<sup>4</sup> The stipulated recovery amount was payable over 3 years (see 2015 Assessment Setting worksheet). 2017 was the last year of this amortization.